| Website | generex.com |
| @GenerexBiotech | |
| Category | BioTech |
| Phone | (416) 364-2551 |
| info@generex.com | |
| Employees | |
| Founded | 1983 |
| TOTAL | $5.75M |
| FUNDING TOTAL | $5.75M |
| Venture Round, 1/11 | $3M |
| Venture Round, 2/12 | $2M |
| Venture Round, 8/12 | $750k |
| DEBT TOTAL | $3.6M |
| Debt, 1/12 | $3.6M |
Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company’s products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation’s under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. The company was founded in 1983 and is based in Toronto, Canada.
